Popular Trials
Diagnostic Biomarker
Amantadine as a Biomarker for Glioblastoma
This trial uses the drug amantadine to help monitor brain tumors in patients with glioblastoma. By measuring how much of the drug is changed into another form in the body, doctors can track tumor activity. This could provide a better way to monitor these aggressive brain tumors.
CAR T-cell Therapy
CAR T Cell Therapy for Pediatric Brain Cancer
This trial uses a patient's own modified immune cells to treat aggressive brain tumors in children and young adults. The immune cells are enhanced to better recognize and attack cancer cells in the brain. This approach has shown remarkable results in treating certain cancers and is now being explored for brain tumors.
Popular Filters
Trials for Diffuse Intrinsic Pontine Glioma Patients
Chemotherapy
PF-07799544 for Cancer
This trial tests a new cancer medicine, PF-07799544, taken regularly as a tablet. It is for people with advanced solid tumors who haven't responded to other treatments. The medicine may be used alone or with other drugs to improve its effectiveness.
CDK4/6 Inhibitor
Abemaciclib + Elacestrant for Brain Metastasis from Breast Cancer
This trial tests a combination of two drugs, elacestrant and abemaciclib, in patients with a specific type of breast cancer. It aims to find the best dose and see how well it works for those whose cancer has spread to the brain. The drugs work by blocking signals that help cancer cells grow and divide. Abemaciclib is a drug that has been approved for the treatment of certain advanced breast cancers.
Virus Therapy
BXQ-350 for Brain Tumor
This trial will test the safety of BXQ-350 in children with newly diagnosed brain tumors, with the goal of determining the maximum tolerated dose. BXQ-350 will be given by IV infusion, along with radiation therapy. The study will enroll patients at increasing dose levels of BXQ-350, in order to determine the maximum tolerated dose.
Trials for Pituitary Adenomas Patients
Chemotherapy
PF-07799544 for Cancer
This trial tests a new cancer medicine, PF-07799544, taken regularly as a tablet. It is for people with advanced solid tumors who haven't responded to other treatments. The medicine may be used alone or with other drugs to improve its effectiveness.
CDK4/6 Inhibitor
Abemaciclib + Elacestrant for Brain Metastasis from Breast Cancer
This trial tests a combination of two drugs, elacestrant and abemaciclib, in patients with a specific type of breast cancer. It aims to find the best dose and see how well it works for those whose cancer has spread to the brain. The drugs work by blocking signals that help cancer cells grow and divide. Abemaciclib is a drug that has been approved for the treatment of certain advanced breast cancers.
Trials for Metastatic Patients
Chemotherapy
PF-07799544 for Cancer
This trial tests a new cancer medicine, PF-07799544, taken regularly as a tablet. It is for people with advanced solid tumors who haven't responded to other treatments. The medicine may be used alone or with other drugs to improve its effectiveness.
CDK4/6 Inhibitor
Abemaciclib + Elacestrant for Brain Metastasis from Breast Cancer
This trial tests a combination of two drugs, elacestrant and abemaciclib, in patients with a specific type of breast cancer. It aims to find the best dose and see how well it works for those whose cancer has spread to the brain. The drugs work by blocking signals that help cancer cells grow and divide. Abemaciclib is a drug that has been approved for the treatment of certain advanced breast cancers.
BTK Inhibitor
Chemo-immunotherapy for Pediatric Brain Cancer
This trial tests a new treatment combining two drugs, ibrutinib and indoximod, with chemotherapy for young patients whose brain cancer has not responded to other treatments. The goal is to boost the immune system's ability to fight the cancer by blocking proteins that help cancer cells survive.
Trials With No Placebo
Chemotherapy
PF-07799544 for Cancer
This trial tests a new cancer medicine, PF-07799544, taken regularly as a tablet. It is for people with advanced solid tumors who haven't responded to other treatments. The medicine may be used alone or with other drugs to improve its effectiveness.
CDK4/6 Inhibitor
Abemaciclib + Elacestrant for Brain Metastasis from Breast Cancer
This trial tests a combination of two drugs, elacestrant and abemaciclib, in patients with a specific type of breast cancer. It aims to find the best dose and see how well it works for those whose cancer has spread to the brain. The drugs work by blocking signals that help cancer cells grow and divide. Abemaciclib is a drug that has been approved for the treatment of certain advanced breast cancers.
Virus Therapy
BXQ-350 for Brain Tumor
This trial will test the safety of BXQ-350 in children with newly diagnosed brain tumors, with the goal of determining the maximum tolerated dose. BXQ-350 will be given by IV infusion, along with radiation therapy. The study will enroll patients at increasing dose levels of BXQ-350, in order to determine the maximum tolerated dose.
View More Related Trials
Frequently Asked Questions
Introduction to brain tumor
What are the top hospitals conducting brain tumor research?
When it comes to cutting-edge clinical trials in the realm of brain tumors, several top hospitals are leading the charge. At Memorial Sloan Kettering Cancer Center in New york, researchers are currently conducting nine active brain tumor trials, building upon a remarkable history of 52 completed studies since their first recorded trial back in 2003. The M D Anderson Cancer Center in Houston is also making significant strides with eight ongoing brain tumor trials and a commendable track record of 43 previously conducted studies since initiating their inaugural trial in 2004. Meanwhile, at Washington University School of Medicine in Saint Louis, seven active brain tumor trials are underway alongside a cumulative total of 32 previous investigations that have contributed to our understanding of this complex condition since their first recorded trial also taking place in 2004.
Additionally adding itself to this list is Boston's esteemed Dana-Farber Cancer Institute which boasts six ongoing clinical tests pertaining to brain tumors while they hold credit for pioneering thirty-one experiments from as long ago as when they started investigating these cases backin2002.Cincinnati Children's Hospital Medical Center may offer fewer active trials compared to others on this list; nevertheless, its five current brain tumor clinical trials and contribution towards paving new paths through fourteen previously held investigations must not be overlooked - theirs can be traced all the way back twenty-five years ago startingfrom1996.
These distinguished hospitals represent beacons of hope within the field of neuro-oncology and serve as testaments to the unwavering dedication displayed by medical professionals worldwide. Through relentless research efforts and innovative clinical trials, these institutions strive for breakthroughs that will ultimately improve outcomes and quality-of-life for individuals battling brain tumors. The collective pursuit for answers continues unabatedly as we strive towards better treatment options and approaches against these formidable adversaries
Which are the best cities for brain tumor clinical trials?
When it comes to brain tumor clinical trials, several cities are leading the way in research and treatment. New york has 27 active trials focused on studying PF-07284890, Memantine Hydrochloride, and other treatments. Los Angeles follows closely behind with 24 ongoing studies exploring PF-07284890, Nivolumab, and treatment cohorts. Houston and Boston also have 24 active trials each that examine various treatments for brain tumors. Lastly, Saint Louis contributes to this important research with 16 active trials investigating options like PF-07284890, Radiation Therapy, and Memantine Hydrochloride. These cities offer individuals dealing with brain tumors opportunities to participate in cutting-edge clinical trials that advance our understanding of these complex diseases and potentially improve patient outcomes.
Which are the top treatments for brain tumor being explored in clinical trials?
Exciting advancements in brain tumor treatment are being explored through rigorous clinical trials. The top contenders include radiation therapy, a proven method with two active trials and a total of 10 all-time brain tumor trials since its introduction in 1997. Another promising approach is the IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes, currently under investigation in two ongoing trials and one all-time trial, starting from 2020. Additionally, G207 has also captured attention with two active and two all-time brain tumor trials since its initial listing in 2016. These innovative treatments offer hope for patients battling this complex condition, bringing us closer to finding more effective solutions against brain tumors.
What are the most recent clinical trials for brain tumor?
Promising advancements in brain tumor research have emerged through recent clinical trials, offering hope and potential breakthroughs for patients. One notable trial involves Group A (Dose Escalation), which aims to explore innovative treatment approaches for brain tumors. Additionally, Arm A - DIPG focuses specifically on diffuse intrinsic pontine gliomas (DIPGs), a rare but devastating form of brain tumor that primarily affects children. Another study investigates the efficacy of dapagliflozin, a medication known for its use in managing diabetes, as a potential therapeutic option for brain tumors. Moreover, Group II explores the combination of temozolomide and selinexor to enhance outcomes in patients with brain tumors. Furthermore, tepotinib holds promise as an investigational treatment option for this challenging condition. These ongoing trials signify significant progress toward improving treatments and patient outcomes within the field of neuro-oncology.
What brain tumor clinical trials were recently completed?
In recent years, several clinical trials focusing on brain tumor treatment have been successfully concluded, bringing hope to patients and advancing medical knowledge in this challenging field. Notably, the investigational agent 18F fluciclovine underwent two separate trials sponsored by Blue Earth Diagnostics, with completion dates in August and October of 2020. Additionally, Emory University conducted a trial for WP1066 that reached its conclusion in May 2020. These significant achievements highlight the dedication of institutions like Dana-Farber Cancer Institute and M.D. Anderson Cancer Center who completed their ALRN-6924 trial in November 2018 and STAT3 Inhibitor WP1066 trial in July 2018 respectively. While ongoing research continues to accelerate progress against brain tumors, these completed trials represent important milestones towards improved therapies.
Note: The answer has been revised for clarity and simplicity while maintaining accuracy regarding recently completed brain tumor clinical trials